読み込み中
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
前日終値
$159.78
+$7.73 · +5.08%
日中の時刻はETです。市場データは遅延する場合があります。
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
日中レンジ
現在 $159.78
52週レンジ
現在 $159.78
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
62
割安
センチメント
45
まちまち
リスク
55
やや高いリスク
モメンタム
70
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
日中レンジ
現在 $159.78
52週レンジ
現在 $159.78
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3.77億 USD | 3.13億 USD | 2.45億 USD | 2.04億 USD | 1.32億 USD |
| 売上原価 | 1.86億 USD | 1.8億 USD | 1.55億 USD | 1.19億 USD | 8062万 USD |
| 粗利益 | 1.91億 USD | 1.33億 USD | 8972.9万 USD | 8423.5万 USD | 5171.3万 USD |
| 研究開発 | 8028.5万 USD | 9085.2万 USD | 1.07億 USD | 1.2億 USD | 6907.2万 USD |
| 販売・一般管理 | 2.47億 USD | 2.18億 USD | 1.9億 USD | 2.13億 USD | 1.36億 USD |
| 営業費用 | 3.27億 USD | 3.54億 USD | 3.07億 USD | 3.19億 USD | 2.04億 USD |
| 受取利息 | 1136.4万 USD | 1534.4万 USD | 1436.5万 USD | 306.2万 USD | 43.5万 USD |
| 支払利息 | — | 2.9万 USD | 5000 USD | 8万 USD | 36.7万 USD |
| 減価償却費と償却費 | 2485.3万 USD | 3143.2万 USD | 2931万 USD | 1651.4万 USD | 975万 USD |
| 営業利益 | −1.36億 USD | −2.21億 USD | −2.17億 USD | −2.35億 USD | −1.53億 USD |
| 純利益 | −7767万 USD | −2.09億 USD | −2.05億 USD | −2.18億 USD | −1.52億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2.77億0.01%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2.65億0.34%787.4億 USD0.19%$278.94+0.49%
ARK Innovation ETFARKK2.19億3.18%55.62億 USD0.75%$89.62+2.31%
Vanguard Morningstar Small-Cap ETFVB2億0.11%1853億 USD0.03%$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI1.81億1.84%98.74億 USD0.35%$153.77+3.00%
ARK Genomic Revolution ETFARKG1.75億8.55%15.57億 USD0.75%$51.30+4.08%
Vanguard Morningstar Small-Cap Growth ETFVBK1.15億0.25%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF1.06億0.11%954億 USD0.05%$235+0.80%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMARK Innovation ETFARKKVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIARK Genomic Revolution ETFARKGVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
